PHARMAC Pharmaceutical Management Agency

28 November 2014

TENDER RESULTS

PHARMAC has resolved to award tenders for Sole Subsidised Supply Status and Hospital Supply Status for some products included in the 2013/14 Invitation to Tender, dated 07 November 2013.

Some of the pharmaceuticals that will be delisted when the period of Sole Subsidised Supply/Hospital Supply Status commences may be subject to existing listing contracts with PHARMAC. Suppliers of pharmaceuticals that are subject to such contracts should continue to supply their pharmaceuticals under those contracts. PHARMAC will continue to subsidise those pharmaceuticals accordingly until such time as those pharmaceuticals are delisted.

Notification of Product Changes (NOPC) forms and Pharmacodes

Please note that for any changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to notify any changes to PHARMAC and the Pharmacy Guild of New Zealand by 4pm on the **12**th **of the month prior to the date of subsidy change**. More information and NOPC forms can be found on our website – <u>http://www.pharmac.health.nz/medicines/how-medicines-are-funded/new-funding-applications/pharmaceutical-product-specifications-the-change-process</u>

Where a product does not have a current Pharmacode, suppliers are required to ensure that a Pharmacode has been obtained from the Pharmacy Guild of New Zealand before the 12th of the month prior to the date of listing. PHARMAC cannot list a product (and pharmacies cannot claim) without the correct Pharmacode.

2013/14 Tender – Sole Subsidised Supply Status or Hospital Supply Status applies until 30 June 2017

CORRECTION to October 2014 tender notification: in **bold** and strikethrough

Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule

1. Tenders awarded to pharmaceuticals where at least one other brand or pack size is listed.

The decisions were as follows:

Chemical Name	Presentation; Pack size and type	Current subsidy and (price)	New subsidy and price	Sole supply brand (Supplier)	Date of listing/subsidy change for tender winning brand	Date of reference pricing of other listed brands	Sole Subsidised Supply date (and delisting of other listed brands)	Brand (Supplier) affected by reference pricing and delisting	
Ezetimibe ^{1.}	tab 10 mg; 30 tablet, blister pack	\$34.43	\$3.35	Ezemibe (Mylan)	1 June 2015	1 August 2015	1 November 2015	Ezetrol (Mylan MSD)	
1. A Brand Switch Fee of \$4.33 is payable from 1 November 2015 until 1 February 2016									

Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule

2. Tenders awarded to listed pharmaceuticals where at least one other brand or pack size is listed **no brand is listed**.

The decisions were as follows:

Chemical Name	Presentation; Pack size and type	Current pack price	New pack price	Hospital Supply Brand (Supplier)	DV Limit	Date of price change	Hospital Supply Status date
Ezetimibe	tab 10 mg; 30 tablet, blister pack	\$34.43	\$3.35	Ezemibe (Mylan)	1%	1 June 2015	1 August 2015

2013/14 Tender – Sole Subsidised Supply Status or Hospital Supply Status applies until 30 June 2017

Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule

3. Tenders awarded to listed pharmaceuticals where only the current brand is listed.

Chemical name	Presentation; Pack size and type	Current subsidy and (price)	New subsidy and price	Sole supply brand (Supplier)	Date of subsidy change	Sole Subsidised Supply date
Allopurinol	tab 100 mg; 1,000 tablet, bottle	\$15.90	\$15.11	Apo-Allopurinol (Apotex)	1 January 2015	1 April 2015
Allopurinol	tab 300 mg; 500 tablet, bottle	\$16.75	\$15.91	Apo-Allopurinol (Apotex)	1 January 2015	1 April 2015
Permethrin	crm 5%; 30 g OP, plastic tube	\$4.20	\$4.20	Lyderm (API)	1 February 2015	1 May 2015
Zinc sulphate	cap 137.4 mg (50 mg elemental); 100 capsule, bottle	\$11.00	\$11.00	Zincaps (Aspen Pharmacare)	1 January 2015	1 April 2015

Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule

4. Tenders awarded to listed pharmaceuticals where only the current brand is listed.

The decisions were as follows:

Chemical Name	Presentation; Pack size and type	Current pack price	New pack price	Hospital Supply Brand (Supplier)	DV Limit	Date of price change	Hospital Supply Status date
Allopurinol	tab 100 mg; 1,000 tablet, bottle	\$15.90	\$15.11	Apo-Allopurinol (Apotex)	1%	1 January 2015	1 March 2015
Allopurinol	tab 300 mg; 500 tablet, bottle	\$16.75	\$15.91	Apo-Allopurinol (Apotex)	1%	1 January 2015	1 March 2015
Ephedrine	inj 30 mg per ml,1 ml ampoule; 10 ampoules	\$66.00	\$51.48	Max Health (Max Health)	1%	1 January 2015	1 March 2015
Permethrin	crm 5%; 30 g, plastic tube	\$4.20	\$4.20	Lyderm (API)	1%	1 February 2015	1 April 2015
Zinc sulphate	cap 137.4 mg (50 mg elemental); 100 capsule, bottle	\$11.00	\$11.00	Zincaps (Aspen Pharmacare)	1%	1 January 2015	1 March 2015

For products included in the 2012/13 or the 2013/14 Invitation to Tender where no announcement has yet been made, either a decision is still pending or is provisional, subject to the product gaining market approval and being available to supply, and subject to PHARMAC Board (or its delegate) approval. We will keep you informed of any updates regarding such tender products as decisions are made.

If you have any queries regarding this notification please contact PHARMAC on 0800 66 00 50.